N Engl J Med 2022 Feb 17
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Abstract
Background
Darolutamide is a potent androgen-receptor inhibitor that has been associated with increased overall survival among patients with nonmetastatic, castration-resistant prostate cancer. Whether a combination of darolutamide, androgen-deprivation therapy, and docetaxel would increase survival among patients with metastatic, hormone-sensitive prostate cancer is unknown.
Methods
In this international, phase 3 trial, we randomly assigned patients with metastatic, hormone-sensitive prostate cancer in a 1:1 ratio to receive darolutamide (at a dose of 600 mg [two 300-mg tablets] twice daily) or matching placebo, both in combination with androgen-deprivation therapy and docetaxel. The primary end point was overall survival.
Results
The primary analysis involved 1306 patients (651 in the darolutamide group and 655 in the placebo group); 86.1% of the patients had disease that was metastatic at the time of the initial diagnosis. At the data cutoff date for the primary analysis (October 25, 2021), the risk of death was significantly lower, by 32.5%, in the darolutamide group than in the placebo group (hazard ratio 0.68; 95% confidence interval, 0.57 to 0.80; P<0.001). Darolutamide was also associated with consistent benefits with respect to the secondary end points and prespecified subgroups. Adverse events were similar in the two groups, and the incidences of the most common adverse events (occurring in ≥10% of the patients) were highest during the overlapping docetaxel treatment period in both groups. The frequency of grade 3 or 4 adverse events was 66.1% in the darolutamide group and 63.5% in the placebo group; neutropenia was the most common grade 3 or 4 adverse event (in 33.7% and 34.2%, respectively).
Conclusions
In this trial involving patients with metastatic, hormone-sensitive prostate cancer, overall survival was significantly longer with the combination of darolutamide, androgen-deprivation therapy, and docetaxel than with placebo plus androgen-deprivation therapy and docetaxel, and the addition of darolutamide led to improvement in key secondary end points. The frequency of adverse events was similar in the two groups. (Funded by Bayer and Orion Pharma; ARASENS ClinicalTrials.gov number, NCT02799602.).
Related Questions
Is rPFS endpoint from CAPItello-281 sufficient to adopt capivasertib + abiraterone for all PTEN-deficient mHSPC?
Not automatically for every PTEN-deficient patient. But rPFS is sufficient to establish capivasertib + abiraterone as a legitimate standard treatment option in appropriately selected patients.CAPItello-281 was unequivocally positive for its primary endpoint: median rPFS was 33.2 versus 25.7 months, ...
How do you choose between ADT/Abiraterone/Capivasertib vs other triplets for fit patients with de novo high-volume mHSPC and near-complete PTEN loss?
Based on prospective randomized controlled trials, the only treatment that has proven benefit in this setting is the triplet with ADT/abiraterone and Capivasertib. I like this combination in particular for fit patients because the side effect profile should allow them to continue to maintain their f...
For patients with high-volume hormone-sensitive prostate cancer, would you consider shortening the docetaxel course to 4 cycles to facilitate better tolerance?
My default here is always evidence-based medicine, in which 6 cycles of docetaxel were given as part of either concurrent triplet therapy (ARASENS or PEACE-1) or sequential triplet therapy (ARCHES, TITAN), without prednisone. For those who develop intolerance, a dose reduction or growth factor suppo...
What are your top takeaways in GU Cancers from ESMO 2024?
1. Tivozanib–nivolumab vs tivozanib monotherapy in patients with renal cell carcinoma (RCC) following 1 or 2 prior therapies including an immune checkpoint inhibitor (ICI): Results of the phase III TiNivo-2 study. This trial confirmed (along with CONTACT-03: cabozantinib +/- atezolizumab) that cont...
How would you approach a patient with prostate cancer with PSMA+ non-regional lymph nodes?
If we take the question at face value, this is a patient with de novo mHSPC and the treatment recommendation would be ADT (level 1) + ARPI (level 1) + RT to primary (level 1) and consideration of RT to metastatic sites (level 3 data).However, I would use one of the multiple PSMA-RADS-like scoring sy...
How do you manage de novo high volume mCSPC with both BRCA2 mutation and MSI-H on somatic testing?
This is a very rare but interesting scenario. Presumably in this case, the BRCA2 mutation is a passenger event in the setting of high TMB as a result of MMRD/MSI high disease, which has been reported. Typically these BRCA alterations are monoallelic and the tumors lack homologous repair deficiency a...
Would you change AR signaling inhibitor in a patient with high volume metastatic castration-sensitive prostate cancer who started darolutamide with initial plan for docetaxel but in whom chemotherapy was eventually deferred?
The ARASENS trial showed a survival benefit for the combination of ADT with chemotherapy and Darolutamide in mHSPC. In a patient with high-volume disease who has been initiated on Darolutamide but in whom chemotherapy was planned but then deferred, I would continue with Darolutamide if the patient i...
How long after initiating ADT/androgen blockade is it acceptable to start docetaxel in a patient with high burden, de-novo metastatic HSPC where you are recommending triplet therapy?
In ARASENS, patients were allowed to enroll if they had received no more than 3 months of ADT prior to starting docetaxel +/- darolutamide. The biologic underpinnings suggest that the combination is most likely to be effective if given together. Therefore, I generally prefer to start the patient on ...
What clinical and pathological features do you consider when deciding which androgen receptor targeted agent to combine with ADT for a patient with newly diagnosed castrate sensitive metastatic prostate cancer?
Regarding which novel hormonal agent I use with ADT, there are no specific pathologic features which suggest that any one agent is better than any others as far as I know, so I do not consider that in the decision. The primary reasons why I choose an agent are based on adverse events and side effect...
Do you treat de novo metastatic hormone sensitive prostate cancer presenting with a paraneoplastic syndrome more aggressively?
For these patients, I will likely add a GnRH antagonist early on to drop testosterone quickly. Depending on performance status and other patient characteristics, we still go through the discussion of adding docetaxel, abiraterone, enzalutamide, and apalutamide (I generally add about 3-4 weeks after ...
Would you give ADT + docetaxel -> darolutamide for a low risk castrate sensitive metastatic prostate cancer patient given ARASENS results?
ARASENS was designed during the era of docetaxel plus ADT emerging as the standard of care for men with mHSPC irrespective of disease volume, based on the improved OS observed in STAMPEDE for a largely de novo mHSPC patient population, where there was no heterogeneity observed for the OS benefit in ...
In light of ARASENS presented at GU ASCO 2022, how do you approach treatment of de novo metastatic hormone sensitive prostate cancer?
There are multiple factors that go into treatment decisions for men with mHSPC, but two of the most important are volume of disease and de novo vs relapsed disease (i.e. prior local therapy). Volume of disease is one of the major factors for deciding on the benefits of docetaxel, with very limited b...